Related Experiment Video
Updated: Jul 25, 2026
10:35
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
18.4K
Dynamic Observation: Immune-Privileged Microenvironment Limited the Effectiveness of Immunotherapy in an Intraocular
Tianchang Tao1,2,3, Yang Liu4, Jun Zhang5
1Department of Ophthalmology, Peking University People's Hospital Eye Diseases and Optometry Institute, Beijing, China.
Ophthalmic Research
|April 10, 2022
Summary
Immunotherapy shows limited success in treating intraocular metastasis (IM) due to ocular tissue properties hindering CD8+ T-cell infiltration. Enhancing T-cell activity is crucial for improving visual outcomes in IM patients.
Area of Science:
- Oncology
- Immunology
- Ophthalmology
Background:
- Intraocular metastasis (IM) affects 8-10% of patients with metastatic cancer.
- Current immunotherapies offer limited visual benefit for IM.
- Mechanisms behind immunotherapy inefficiency in IM require investigation.
Purpose of the Study:
- To establish and utilize a novel mouse model for studying intraocular metastasis (IM).
- To evaluate the efficacy of combined anti-PD-1 and anti-CTLA4 immunotherapy in IM.
- To elucidate the immune microenvironment's role in IM progression and treatment response.
Main Methods:
- Established a mouse model of IM via intracarotid injection of melanoma cells.
- Assessed disease progression using ophthalmic and histological examinations.
- Characterized tumor-infiltrating CD8+ T cells and their cytotoxicity.
Main Results:
- Immunotherapy inhibited IM progression but did not prevent eye rupture.
- Ocular tissue PD-L1 expression impeded CD8+ T-cell infiltration in uveal metastasis.
- Despite high cytotoxicity, infiltrating T cells were inhibited by FasL+ PD-L1+ ocular tissue.
Conclusions:
- Immunotherapy demonstrates potential in managing IM disease progression.
- Enhancing CD8+ T-cell function is key to improving visual outcomes in IM.
